Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Is Recursion Pharmaceuticals Stock a Buy?
Recursion is seeking to revolutionize the way we develop drugs. If it's successful, the biotech will reap immense benefits.
Recursion Pharmaceuticals, Inc. (RXRX) Q2 2024 Earnings Call Transcript
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q2 2024 Earnings Conference Call August 8, 2024 5:00 PM ET Company Participants Chris Gibson - Co-Founder and Chief Executive Officer Najat Khan - Chief R&D and Commercial Officer Dave Hallett - Chief Executive Officer (Interim) and Chief Scientific Officer, Exscientia Conference Call Participants Chris Gibson Hi, everybody. My name is Chris Gibson, Co-Founder and CEO of Recursion, delighted to be joining you on our L(earnings) today.
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Tops Revenue Estimates
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.38 per share a year ago.
Is Recursion Pharmaceuticals a Millionaire-Maker?
Recursion could have three different revenue streams one day. Right now, it only has one but another may soon be within reach.
Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: Here's Why
Recursion Pharmaceuticals (RXRX) closed at $8.19 in the latest trading session, marking a -1.92% move from the prior day.
Down About 47% This Year: Is Recursion Pharmaceuticals a Buy on the Dip?
Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.
Wall Street Analysts Predict a 43.73% Upside in Recursion Pharmaceuticals (RXRX): Here's What You Should Know
The consensus price target hints at a 43.7% upside potential for Recursion Pharmaceuticals (RXRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Recursion Pharmaceuticals Stock a Buy?
Recursion Pharmaceuticals wants to disrupt drug development. It's leaning on new information technology and automation methods.
1 Reason to Buy Recursion Pharmaceuticals Stock and 2 Reasons to Sell
Recursion Pharmaceuticals is looking to revolutionize the drug development process. The biotech's strategy has yet to deliver major medical breakthroughs.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing
Recursion Pharmaceuticals (RXRX) reachead $9.38 at the closing of the latest trading day, reflecting a +0.43% change compared to its last close.
Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery
This thesis makes the case for an investment in Recursion Pharmaceuticals operating as a TechBio which "industrializes" the process of drug discovery in contrast to a typical biotech. The difference between TechBio and biotech may appear subtle, but is an important one that may have motivated Nvidia to invest $50 million. Based on the value of its platform and data assets, it is a buy with a 48.5% upside potential.
